Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Draft scoping document for ICER review of RA treatments

Draft scoping document for ICER review of RA treatments PharmacoEconomics & Outcomes News 759, p2 - 13 Aug 2016 Draft scoping document for ICER review of RA treatments The US Institute for Clinical and Economic Review (ICER) has published a draft scoping document for its review of drugs for the treatment of rheumatoid arthritis (RA). The document will be open to comments from stakeholders for 3 weeks. When this topic was initially announced, ICER suggested that it might also review treatments for psoriatic arthritis (PA), but feedback from patient groups, drug companies and other stakeholders indicated that RA and PA have important differences in patient-centered outcomes and should be considered separately. ICER has therefore decided that the current review will cover RA treatments only, and PA treatments will be the focus of a later review. Following the initial 3-week public comment period, a revised scoping document is expected to be posted on 29 August 2016 and will guide development of a Draft Evidence Report, which is expected to be posted mid November 2016 and followed by a 4-week public comment period. The ICER report on RA treatments will be discussed at a public meeting of the Midwest Comparative Effectiveness Public Advisory Council (CEPAC) on 26 January 2017. Institute http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Draft scoping document for ICER review of RA treatments

PharmacoEconomics & Outcomes News , Volume 759 (1) – Aug 13, 2016
Download PDF
1 page

Draft scoping document for ICER review of RA treatments

Abstract

PharmacoEconomics & Outcomes News 759, p2 - 13 Aug 2016 Draft scoping document for ICER review of RA treatments The US Institute for Clinical and Economic Review (ICER) has published a draft scoping document for its review of drugs for the treatment of rheumatoid arthritis (RA). The document will be open to comments from stakeholders for 3 weeks. When this topic was initially announced, ICER suggested that it might also review treatments for psoriatic arthritis (PA), but feedback from...
Loading next page...
 
/lp/springer-journals/draft-scoping-document-for-icer-review-of-ra-treatments-00Q63scJkC

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2016 by Springer International Publishing Switzerland
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
DOI
10.1007/s40274-016-3267-y
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 759, p2 - 13 Aug 2016 Draft scoping document for ICER review of RA treatments The US Institute for Clinical and Economic Review (ICER) has published a draft scoping document for its review of drugs for the treatment of rheumatoid arthritis (RA). The document will be open to comments from stakeholders for 3 weeks. When this topic was initially announced, ICER suggested that it might also review treatments for psoriatic arthritis (PA), but feedback from patient groups, drug companies and other stakeholders indicated that RA and PA have important differences in patient-centered outcomes and should be considered separately. ICER has therefore decided that the current review will cover RA treatments only, and PA treatments will be the focus of a later review. Following the initial 3-week public comment period, a revised scoping document is expected to be posted on 29 August 2016 and will guide development of a Draft Evidence Report, which is expected to be posted mid November 2016 and followed by a 4-week public comment period. The ICER report on RA treatments will be discussed at a public meeting of the Midwest Comparative Effectiveness Public Advisory Council (CEPAC) on 26 January 2017. Institute

Journal

PharmacoEconomics & Outcomes News – Springer Journals

Published: Aug 13, 2016

There are no references for this article.